A Prospective, Multicenter Study on Best Clinical Use of Imatinib in the Advanced Gastrointestinal Stromal Tumors
Open-label, multicenter study of imatinib (400mg/die p.o.)in patients with advanced gastrointestinal stromal tumors. Patients will be treated for up to 12 months. Data regarding its best clinical use in terms of tumor response, survival, tolerability and safety profile will be prospectively collected.
Advanced Gastrointestinal Stromal Tumors
DRUG: Imatinib
tumor response /RecIST criteria), first 2 months monthly, then every 3 months
SAE and tolerability profile, ongoing basis|OS, DFS, 12 months|effects of the therapy when combined with other treatment modalities i.e. surgery of residual disease., 12 months|which early predictive factors of tumor response may be of relevance, i.e. conventional pathologic characteristics of tumor and radiological aspects., 12 months
Open-label, multicenter study of imatinib (400mg/die p.o.)in patients with advanced gastrointestinal stromal tumors. Patients will be treated for up to 12 months. Data regarding its best clinical use in terms of tumor response, survival, tolerability and safety profile will be prospectively collected.